In this study, we found that the involvement of SV2A in the pathogenesis and development of AD appears to be mediated by the PI3K signaling pathway, as upregulation of SV2A down-regulated the expression of PI3K (Figure 5A) and treatment with the PI3K inhibitor LY294002 blocked this effect (Figure 5D). This evidence concerns the gene SV2A and Alzheimer disease.